<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Asia Pac Allergy</journal-id><journal-id journal-id-type="publisher-id">APA</journal-id><journal-title-group><journal-title>Asia Pacific Allergy</journal-title></journal-title-group><issn pub-type="ppub">2233-8276</issn><issn pub-type="epub">2233-8268</issn><publisher><publisher-name>Asia Pacific Association of Allergy, Asthma and Clinical Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3206231</article-id><article-id pub-id-type="pmid">22053295</article-id><article-id pub-id-type="doi">10.5415/apallergy.2011.1.1.36</article-id><article-categories><subj-group subj-group-type="heading"><subject>Educational &#x00026; Teaching Material</subject></subj-group></article-categories><title-group><article-title>Irritable bowel syndrome - An inflammatory disease involving mast cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Philpott</surname><given-names>Hamish</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gibson</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Thien</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Monash University, Victoria 3800, Australia.</aff><aff id="A2"><label>2</label>Box Hill Hospital, Box Hill, Victoria 3128, Australia.</aff><author-notes><corresp>
Correspondence: Frank Thien. Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill, Victoria 3128, Australia. Tel: +61-3-9095-2415, Fax: +61-3-9899-6810, <email>francis.thien@easternhealth.org.au</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>26</day><month>4</month><year>2011</year></pub-date><volume>1</volume><issue>1</issue><fpage>36</fpage><lpage>42</lpage><history><date date-type="received"><day>28</day><month>11</month><year>2010</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Irritable bowel syndrome (IBS) is traditionally defined as a functional disorder - that is the presence of symptoms in the absence of demonstrable pathological abnormalities. In recent times, low grade inflammatory infiltrates in both the small and large bowel of some patients with IBS - often rich in mast cells, along with serological markers of low grade inflammation have focussed attention on IBS as an inflammatory disease. The observation that mast cells often lie in close association to enteric neurons, and <italic>in-vitro</italic> and <italic>in-vivo</italic> animal studies demonstrating that mast cell mediators may influence enteric motility provides a biologically plausible causal mechanism in IBS. Pilot studies on patients with IBS using the mast cell stabiliser sodium cromoglycate ('proof of concept') have been encouraging. The essential question remains why mast cells infiltrate the bowel of IBS patients. A disturbance of the 'brain-gut axis' is the current favoured hypothesis, whereby childhood stress or psychiatric comorbidity act via neuro-immune mechanisms to modulate low grade inflammation. An alternative hypothesis is that food allergy may be responsible. Serum specific IgE, and skin prick tests are not elevated in IBS patients, suggesting type 1 IgE mediated food allergy is not the cause. However questionnaire based studies indicate IBS patients have higher rates of atopic disease, and increased bronchial reactivity to methacholine has been demonstrated. In this review, we highlight the potential role of mast cells in IBS, and current and future research directions into this intriguing condition.</p></abstract><kwd-group><kwd>IBS</kwd><kwd>Mast cells</kwd><kwd>Atopy</kwd><kwd>Inflammation</kwd><kwd>Immunology</kwd></kwd-group></article-meta></front><body><p>Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and causes considerable morbidity amongst its sufferers [<xref ref-type="bibr" rid="B1">1</xref>]. Long defined as a functional gastrointestinal disorder (implying the lack of demonstrable pathological abnormalities) IBS is increasingly viewed as a low grade inflammatory disorder [<xref ref-type="bibr" rid="B2">2</xref>]. Both histological specimens obtained at endoscopy and serological cytokine studies have demonstrated low grade inflammation in IBS [<xref ref-type="bibr" rid="B3">3</xref>]. Mast cells (MC) appear to play a particularly important role, and pilot 'intention to treat' studies using MC stabilisers have yielded encouraging results [<xref ref-type="bibr" rid="B4">4</xref>]. The observation that mast cells often lie in close association to enteric neurons and <italic>in vitro</italic> and <italic>in vivo</italic> animal studies demonstrating that MC mediators may influence enteric motility provide a biologically plausible mechanism of causation in IBS [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Mast cells are normally found in the intestine, but why they may be found in higher density and, more importantly, why they are activated in patients with IBS has yet to be determined. One popular current hypothesis is that IBS represents a disturbance of the 'brain-gut axis' whereby stressful early life events and/or psychiatric co-morbidity mediate low level inflammation and mast cell infiltration of the bowel [<xref ref-type="bibr" rid="B3">3</xref>]. An alternative hypothesis is that food allergy may be responsible [<xref ref-type="bibr" rid="B6">6</xref>]. Traditional measures of type 1 IgE-mediated food allergy, such as serum specific IgE and RAST testing, are usually negative, but questionnaire-based studies indicate an increased prevalence of atopic disease amongst IBS patients and bronchial provocation testing may be abnormal [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>]. In this review, the evidence for MC involvement in IBS is discussed, and the need for future collaborative research between gastroenterologists and allergist/immunologist alike is highlighted.</p><sec><title>IBS as an inflammatory condition</title><p>IBS is a common condition, with a prevalence of 10-20% being reported in Western countries, India, China and Japan [<xref ref-type="bibr" rid="B8">8</xref>]. Whilst not life-threatening, IBS causes considerable morbidity and is responsible considerable time off work and an impaired quality of life [<xref ref-type="bibr" rid="B9">9</xref>]. Female gender, a family history of IBS, a history of physical or sexual abuse and co-morbid psychiatric disorders are strong risk factors for IBS [<xref ref-type="bibr" rid="B10">10</xref>]. Indeed up to 70% of the patients referred to tertiary centres with IBS meet diagnostic criteria for anxiety or depression [<xref ref-type="bibr" rid="B10">10</xref>]. While this may represent a minority sub-group where uncontrolled symptoms may be the effect rather than the cause, such patients have focussed interest on the 'brain-gut axis' as the explanatory disease model [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>IBS has traditionally been defined in terms of a symptom cluster and classed as a functional gastrointestinal disorder-implying an absence of demonstrable anatomical or histological pathology. The advent of gastrointestinal manometry and motility laboratories in the 1970's lead to a focus on disturbances of motility and, later, to heightened sensitivity to luminal distension or 'visceral hyperalgesia or hypersensitivity' [<xref ref-type="bibr" rid="B11">11</xref>]. Many patients with IBS manifest abnormal colonic or small bowel motility (slow, fast or incoordinate) and/or hyperalgesia, but such physiological abnormalities have not found a place in routine clinical practice or in diagnosis or classification [<xref ref-type="bibr" rid="B11">11</xref>]. The pattern of symptoms remains the cornerstone of diagnosis and classification of functional gut disorders (the Rome III criteria as shown in <xref ref-type="table" rid="T1">Table 1</xref>) [<xref ref-type="bibr" rid="B12">12</xref>]. For patients with IBS, they may then be classified IBS-C (constipation-predominant), IBS-D (diarrhoea-predominant) or IBS-A (alternating) according to their symptom pattern [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The observation that a percentage of patients who suffer from acute gastroenteritis go on to develop IBS renewed interest in IBS as an inflammatory condition [<xref ref-type="bibr" rid="B13">13</xref>]. Follow-up of these patients in multiple centres and cohorts has revealed a tendency to develop IBS-D and have low grade inflammatory infiltrates (often containing MCs) at endoscopy [<xref ref-type="bibr" rid="B3">3</xref>]. Subsequent endoscopic comparisons of patients with IBS-D who did not describe a pre-existing acute infectious gastroenteritis found similar low grade inflammatory changes, allowing the 'inflammatory hypothesis' to be applied more generally [<xref ref-type="bibr" rid="B3">3</xref>].</p></sec><sec><title>Mast cell infiltrates in IBS</title><p>Many but not all human endoscopic biopsy studies of patients with IBS have found increased numbers of MCs in the luminal mucosa (<xref ref-type="table" rid="T2">Table 2</xref>) [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. The density of MCs in both small and large bowel may be increased in patients with IBS, but the results are somewhat contradictory. Some studies demonstrate increased density in the small and not the large bowel and others vice-versa. Increased density of MCs has been found in both male and female patients and in all subtypes of IBS. The presence of MCs per se does not necessarily imply they are pathogenically important unless they are activated. Indeed, Barbara et al demonstrated an increased number of degranulating MCs in patients with IBS compared to that in healthy controls [<xref ref-type="bibr" rid="B17">17</xref>]. Tryptase release from duodenal biopsies was elevated; arguably increased MC numbers should naturally cause increased tryptase following laboratory manipulation of biopsy specimens.</p><p>There have been some attempts to correlate the density of MCs to clinical symptoms [<xref ref-type="bibr" rid="B17">17</xref>]. Several studies have shown an association with the severity of abdominal pain [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. Two groups have examined the associations with psychiatric co-morbidity, particularly anxiety and depression which are commonly described in IBS [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. In only one was the density of MCs in the intestine significantly correlated with the severity of anxiety and depression [<xref ref-type="bibr" rid="B15">15</xref>] .</p></sec><sec><title>A rationale for mast cells as a causative factor for IBS symptomatology</title><p>There are several layers of evidence in support of a major role of MCs in the genesis of symptoms in IBS.</p><p>
    <list list-type="bullet"><list-item><p>MCs are present in the appropriate microenvironment of the gastrointestinal tract. They are found in both the mucosa and serosal layers and express high affinity (FcR&#x003b3;) receptors to IgE [<xref ref-type="bibr" rid="B3">3</xref>]. MCs in humans lie in close proximity to neural endings and may form membrane-membrane interactions [<xref ref-type="bibr" rid="B20">20</xref>]. The factors regulating the close apposition of MCs to enteric neural cells are incompletely understood, but may involve a two-way communication by which MCs produce neurotrophic growth factors, and MCs are in turn attracted by neuropeptides Further research into this complex interplay is clearly needed if the 'brain-gut' axis is to be understood (see above) [<xref ref-type="bibr" rid="B21">21</xref>].</p></list-item><list-item><p>Mediators released from MCs are capable of inducing sensorimotor dysfunction. Degranulation of MCs is associated with release of mediators such as histamine, tryptase and prostaglandins which may influence enteric efferents via proteinase-activated receptors [<xref ref-type="bibr" rid="B22">22</xref>]. Furthermore, a study using mucosal mediators of IBS patients on rat jejunal sensory nerve firing found that the stimulatory effect of the mucosal mediators released from the mucosal biopsies of IBS patients could be inhibited by histamine receptor blockade [<xref ref-type="bibr" rid="B5">5</xref>].</p></list-item><list-item><p>MC activation may cause abdominal symptoms consistent with IBS. Patients with clear IgE-mediated allergic reactions to food often complain of functional abdominal symptoms [<xref ref-type="bibr" rid="B23">23</xref>]. More strikingly, patients with systemic mastocytosis who have an enteric infiltrate often complain of a pattern of abdominal symptoms that fulfil criteria for IBS [<xref ref-type="bibr" rid="B24">24</xref>].</p></list-item><list-item><p>Apparent efficacy of treatments aimed at decreasing MC mediator release and/or infiltration. Sodium cromoglycate is classified as a 'mast cell stabiliser' and has shown promise in pilot 'proof-of-concept' studies to improve the symptoms of IBS patients [<xref ref-type="bibr" rid="B25">25</xref>]. The oral anti-inflammatory 5ASA has been found in one small randomised controlled study to decrease the symptoms of IBS, and this corresponded with a decrease in the density of the MC infiltrate within the colon. Furthermore the mast cell stabiliser and antihistamine (H-1 receptor blocker) ketotifen was found to decrease the symptoms of IBS in a recent placebo controlled trial involving 60 patients (30 in each arm) [<xref ref-type="bibr" rid="B26">26</xref>]. Curiously, the patients who received ketotifen and improved symptomatically at 8 weeks were not less likely than controls to manifest mast cell degranulation (as defined by tryptase or histamine release on endoscopic biopsy specimens) and the intestinal infiltration of mast cells was unchanged following the treatment course [<xref ref-type="bibr" rid="B26">26</xref>]. This led the authors to suggest that H-1 receptor blockade, and not mast cell stabilisation was the likely therapeutic mechanism [<xref ref-type="bibr" rid="B26">26</xref>]. Cleary further research is required.</p></list-item></list>
    </p></sec><sec><title>IBS and the brain-gut axis</title><p>As outlined above, the term 'brain-gut axis' refers to the bi-directional communication between the gut (enteric nervous system, luminal wall) and the central nervous system (including the hypothalamopituitary axis) [<xref ref-type="bibr" rid="B27">27</xref>]. More recently, the complex neuro-immune interactions between the intestinal microflora and the host has been incorporated into this model (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The brain-gut-axis model attempts to explain the complex interplay of factors potentially responsible for the precipitation and perpetuation of IBS and other gastrointestinal conditions. Animal studies have shown that maternal deprivation may result in later sensitivity to manometric gastrointestinal stimuli, whilst stressing an adult rodent can result in increased cortisol releasing hormone (CRH), and colonic MC infiltration and degranulation [<xref ref-type="bibr" rid="B28">28</xref>]. The interplay between stress and the disturbed gastrointestinal motility and sensory function is particularly pertinent given the association between childhood physical and sexual abuse, psychiatric illness, life stress and IBS. Indeed, human studies reveal abnormal colonic motility mimicking IBS in subjects injected with CRH [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>The intestinal microbiota may play an additional modulating role in the brain-gut axis and are the subject of current intense research interest. It is not known why some patients with IBS demonstrate abnormalities in their microbiota, but it is proposed that the spectrum of flora in these patients favours a pro-inflammatory mucosal reaction [<xref ref-type="bibr" rid="B30">30</xref>]. Encouragingly, a few studies suggest a role for probiotics in successfully alleviating the symptoms of IBS [<xref ref-type="bibr" rid="B30">30</xref>].</p></sec><sec><title>IBS and food allergy</title><p>Patients frequently attribute their symptoms to food intake and there is little doubt that food is an important trigger for those symptoms [<xref ref-type="bibr" rid="B23">23</xref>]. There are many mechanisms by which this can occur and these include luminal distension and osmotic effects, direct stimulation of the MCs or enteric nervous system by bioactive chemicals such as salicylates, and food hypersensitivity (non-IgE-mediated) reactions [<xref ref-type="bibr" rid="B31">31</xref>]. However, there is no direct evidence to suggest that classical IgE mediated type 1 allergic reactions to food antigens play a role in the symptoms of IBS [<xref ref-type="bibr" rid="B23">23</xref>]. Skin prick and serum specific IgE antibody testing to common food antigens are generally identical to healthy controls [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>Few studies have examined responses to foods in the gut-associated immune compartment, which may be very different to those in the systemic immune compartment. One approach is to perform the equivalent of skin prick tests via the colonoscope and to look for wheal reactions after the mucosal injection of food antigens. This test, the colonoscopic allergen provocation test (COLAP), showed positive responses to specific food antigens in a significant majority of patients with functional gut symptoms and suspected food hypersensitivity who had normal skin prick and serum specific IgE to common food antigens [<xref ref-type="bibr" rid="B32">32</xref>]. Hence it is conceivable that a percentage of IBS patients have an IgE or other immune-mediated food hypersensitivity that is being 'missed'. There have been no subsequent reports of the further application of the COLAP test or on findings in patients with IBS. This deserves further study.</p><p>IgG antibodies to common food antigens may be detected in the serum of healthy children and adults [<xref ref-type="bibr" rid="B6">6</xref>]. Patients with IBS have elevated titres of these antibodies in some studies, although no correlation between the degree of elevation in IgG and the severity of the symptoms has been demonstrated [<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>]. A randomised controlled trial involving only patients with IBS who were allocated either a sham diet or elimination diet to culprit foods to which the IgG antibodies were elevated demonstrated symptomatic benefit at 12 weeks, but only after data were corrected for adherence [<xref ref-type="bibr" rid="B6">6</xref>]. Healthy controls were not included in this study and IgG antibodies were not measured at the conclusion of the study. Sustained benefit from this food-specific IgG approach has been claimed by another group, but the concurrent use of probiotics reduced the clarity of the findings [<xref ref-type="bibr" rid="B34">34</xref>]. Further studies are warranted. Until a cause-effect relationship is clearly established, the quantitative (and not qualitative difference) in serum IgG to food antigens could conceivably be an epiphenomenon, perhaps related to an inflamed or 'leaky' gut [<xref ref-type="bibr" rid="B35">35</xref>].</p></sec><sec><title>IBS and atopic diseases</title><p>IBS patients are no more likely than the background population to record positive skin prick or serum specific IgE tests to common environmental antigens. Curiously however, there is an increased prevalence of IBS amongst patients with other 'atopic' conditions, according to some studies [<xref ref-type="bibr" rid="B7">7</xref>]. For example, an association was found between allergy patients attending a tertiary hospital clinic and a high proportion of IBS symptoms meeting Rome criteria using a self-report questionnaire [<xref ref-type="bibr" rid="B7">7</xref>]. In a retrospective case control study of more than 7,000 patients attending a general practise setting in the UK, an increased prevalence of allergic rhinitis and asthma amongst patients with lower gastrointestinal symptoms was reported [<xref ref-type="bibr" rid="B36">36</xref>]. It should be pointed out that questionnaire-based studies potentially introduce responder bias; IBS patients may, for example, display a 'learned illness' behaviour and be expected to complain of symptoms without organic cause. Several more objective papers have linked asthma with IBS and have demonstrated increased airway responsiveness to inhaled methacholine and/or reversibility with bronchodilators in IBS patients who do not give a history of asthma or other atopic conditions [<xref ref-type="bibr" rid="B8">8</xref>]. In a study of 133 IBS patients and matched healthy controls, asthma was diagnosed in 15% of the IBS group compared to 1.5% of controls [<xref ref-type="bibr" rid="B8">8</xref>]. By contrast, another group failed to demonstrate an increased prevalence of asthma amongst IBS patients in a study of 42 IBS patients and 42 matched healthy controls [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>Hence it would appear that the association between IBS and atopic conditions is controversial, and that traditional measures of 'atopy' are negative [<xref ref-type="bibr" rid="B7">7</xref>]. Rather the association is based on self reported symptom clusters and/or the objective finding of bronchial hyper-reactivity. As many cases of asthma, particularly of adult onset are apparently unrelated to allergy, other shared cofactors may be responsible for the association, including alterations in sympathetic/ parasympathetic tone [<xref ref-type="bibr" rid="B38">38</xref>]. Further study is needed, perhaps examining the mucosa of both the bronchi and gut of the putative 'asthmatic' IBS subgroup, and correlating the IBS symptoms with respiratory function tests over time.</p></sec><sec><title>Stress as a precipitating factor for food allergy - towards a unifying conceptual framework with treatment implications</title><p>Two opposing models of IBS causation have been outlined:</p><p>
    <list list-type="bullet"><list-item><p>The 'head-down' hypothesis: psychological or physical stress activates the hypothalamic-pituitary axis, central and enteric nervous system to release CRH and neuropeptides to attract MCs to the bowel wall [<xref ref-type="bibr" rid="B39">39</xref>]; and</p></list-item><list-item><p>The 'bottom-up' hypothesis: Food allergens/antigens incite the inflammatory infiltrate [<xref ref-type="bibr" rid="B7">7</xref>].</p></list-item></list>
    </p><p>There is no reason why both forces can't be operating (<xref ref-type="fig" rid="F1">Fig. 1</xref>). This is supported by studies of patients with post-infectious IBS, in which patients with a history of physical or sexual abuse or depression (head-down) are more likely to develop IBS following a self limited episode of acute infectious diarrhoea (bottom-up) [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B40">40</xref>].</p><p>Animal models provide a clue as to how stress may 'prime' a patient to develop a localised inflammatory response to food antigens. Rats that were subjected to stress prior to consumption of a labelled oral antigen (horse-radish peroxidase - HRP) were not only more likely to absorb the HRP, but also more likely to form circulating HRP-specific IgE and develop a denser inflammatory infiltrate containing MCs in the intestinal wall [<xref ref-type="bibr" rid="B28">28</xref>]. While this model is not directly applicable to IBS in humans in that these patients have a normal serum IgE to food antigens, the concept of stress modulating intestinal permeability, antigen presentation and inflammatory cell recruitment may guide future research. Promising avenues of inquiry may include the study of toll-like receptors on enterocytes as well as cytokine and microarray analysis.</p><p>Recent advances in dietary therapy directed at food intolerance (specifically short-chain poorly absorbed carbohydrates) have improved the ability to achieve symptomatic control in the majority of patients with IBS, but this therapy is purely symptomatic and does not address the potential causes of IBS [<xref ref-type="bibr" rid="B41">41</xref>]. In light of the above unifying hypothesis, more pathogenically-related therapy can be proposed. Potential 'head-down' therapies such as the use of antidepressant medication, hypnotherapy and cognitive behavioural therapy, which show benefit in some patients, may be combined with 'bottom-up' therapies such as excluding validly identified food antigens form the diet or pharmacological agents such as mast cell stabilisers, antihistamines and mesalazine, which also have some evidence for efficacy [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B25">25</xref>]. Thus, a dualistic treatment approach based upon the unifying hypothesis may improve therapy in the future (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p></sec><sec><title>Summary</title><p>IBS is one of the most common gastroenterological disorders, yet its aetiology remains elusive. Recent interest has focussed on low grade inflammation, particularly involving MCs in its pathogenesis. The most compelling overall hypothesis to explain the MC infiltrate is of a disturbance of the brain-gut axis, whereby MCs may be attracted to the bowel via neuropeptides - although only animal models support this assertion. While current evidence suggests type 1 IgE-mediated food allergy is an unlikely cause of the MC infiltrate, patients with IBS appear to describe more frequent atopic symptoms and studies of the gut immune compartment have produced some signals that immune-mediated reactions to food antigens may indeed be causally related to symptom genesis. Cleary, IBS represents a fertile soil for research for both gastroenterologists and allergy/immunologists alike.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiller</surname><given-names>R</given-names></name><name><surname>Aziz</surname><given-names>Q</given-names></name><name><surname>Creed</surname><given-names>F</given-names></name><name><surname>Emmanuel</surname><given-names>A</given-names></name><name><surname>Houghton</surname><given-names>L</given-names></name><name><surname>Hungin</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Rubin</surname><given-names>G</given-names></name><name><surname>Trudgill</surname><given-names>N</given-names></name><name><surname>Whorwell</surname><given-names>P</given-names></name></person-group><collab>Clinical Services Committee of the British Society of Gastroenterology</collab><article-title>Guidelines on the irritable bowel syndrome: mechanisms and practical management</article-title><source>Gut</source><year>2007</year><volume>56</volume><fpage>1770</fpage><lpage>1798</lpage><pub-id pub-id-type="pmid">17488783</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>EA</given-names></name><name><surname>Collins</surname><given-names>SM</given-names></name></person-group><article-title>Evolving pathophysiologic models of functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2002</year><volume>122</volume><fpage>2032</fpage><lpage>2048</lpage><pub-id pub-id-type="pmid">12055608</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohman</surname><given-names>L</given-names></name><name><surname>Simr&#x000e9;n</surname><given-names>M</given-names></name></person-group><article-title>Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2010</year><volume>7</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">20101257</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname><given-names>B</given-names></name><name><surname>Vicario</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Ramos</surname><given-names>L</given-names></name><name><surname>Alonso</surname><given-names>C</given-names></name><name><surname>Guilarte</surname><given-names>M</given-names></name><name><surname>de Torres</surname><given-names>I</given-names></name><name><surname>Saperas</surname><given-names>E</given-names></name><name><surname>Santos</surname><given-names>J</given-names></name></person-group><article-title>Clinical benefit in IBS after disodium cromoglycate involves mast cell mediated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>A-30</fpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbara</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Stanghellini</surname><given-names>V</given-names></name><name><surname>de Giorgio</surname><given-names>R</given-names></name><name><surname>Cremon</surname><given-names>C</given-names></name><name><surname>Di Nardo</surname><given-names>G</given-names></name><name><surname>Trevisani</surname><given-names>M</given-names></name><name><surname>Campi</surname><given-names>B</given-names></name><name><surname>Geppetti</surname><given-names>P</given-names></name><name><surname>Tonini</surname><given-names>M</given-names></name><name><surname>Bunnett</surname><given-names>NW</given-names></name><name><surname>Grundy</surname><given-names>D</given-names></name><name><surname>Corinaldesi</surname><given-names>R</given-names></name></person-group><article-title>Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">17241857</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>W</given-names></name><name><surname>Sheldon</surname><given-names>TA</given-names></name><name><surname>Shaath</surname><given-names>N</given-names></name><name><surname>Whorwell</surname><given-names>PJ</given-names></name></person-group><article-title>Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1459</fpage><lpage>1464</lpage><pub-id pub-id-type="pmid">15361495</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>MC</given-names></name><name><surname>Moparty</surname><given-names>B</given-names></name><name><surname>Farhadi</surname><given-names>A</given-names></name><name><surname>DeMeo</surname><given-names>MT</given-names></name><name><surname>Bansal</surname><given-names>PJ</given-names></name><name><surname>Keshavarzian</surname><given-names>A</given-names></name></person-group><article-title>Atopic irritable bowel syndrome: a novel subgroup of irritable bowel syndrome with allergic manifestations</article-title><source>Ann Allergy Asthma Immunol</source><year>2008</year><volume>100</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18254482</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yazar</surname><given-names>A</given-names></name><name><surname>Atis</surname><given-names>S</given-names></name><name><surname>Konca</surname><given-names>K</given-names></name><name><surname>Pata</surname><given-names>C</given-names></name><name><surname>Akbay</surname><given-names>E</given-names></name><name><surname>Calikoglu</surname><given-names>M</given-names></name><name><surname>Hafta</surname><given-names>A</given-names></name></person-group><article-title>Respiratory symptoms and pulmonary functional changes in patients with irritable bowel syndrome</article-title><source>Am J Gastroenterol</source><year>2001</year><volume>96</volume><fpage>1511</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">11374691</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>RL</given-names></name><name><surname>Olden</surname><given-names>KW</given-names></name><name><surname>Naliboff</surname><given-names>BD</given-names></name><name><surname>Bradley</surname><given-names>LA</given-names></name><name><surname>Francisconi</surname><given-names>C</given-names></name><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Creed</surname><given-names>F</given-names></name></person-group><article-title>Psychosocial aspects of the functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1447</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">16678558</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Creed</surname><given-names>FH</given-names></name><name><surname>Olden</surname><given-names>KW</given-names></name><name><surname>Svedlund</surname><given-names>J</given-names></name><name><surname>Toner</surname><given-names>BB</given-names></name><name><surname>Whitehead</surname><given-names>WE</given-names></name></person-group><article-title>Psychosocial aspects of the functional gastrointestinal disorders</article-title><source>Gut</source><year>1999</year><volume>45</volume><issue>Suppl 2</issue><fpage>II25</fpage><lpage>II30</lpage><pub-id pub-id-type="pmid">10457041</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasler</surname><given-names>WL</given-names></name></person-group><article-title>Traditional thoughts on the pathophysiology of irritable bowel syndrome</article-title><source>Gastroenterol Clin North Am</source><year>2011</year><volume>40</volume><fpage>21</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">21333899</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Dumitrascu</surname><given-names>DL</given-names></name></person-group><article-title>Rome III: New standard for functional gastrointestinal disorders</article-title><source>J Gastrointestin Liver Dis</source><year>2006</year><volume>15</volume><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">17013448</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiller</surname><given-names>R</given-names></name><name><surname>Garsed</surname><given-names>K</given-names></name></person-group><article-title>Postinfectious irritable bowel syndrome</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>1979</fpage><lpage>1988</lpage><pub-id pub-id-type="pmid">19457422</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremon</surname><given-names>C</given-names></name><name><surname>Gargano</surname><given-names>L</given-names></name><name><surname>Morselli-Labate</surname><given-names>AM</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Cogliandro</surname><given-names>RF</given-names></name><name><surname>De Giorgio</surname><given-names>R</given-names></name><name><surname>Stanghellini</surname><given-names>V</given-names></name><name><surname>Corinaldesi</surname><given-names>R</given-names></name><name><surname>Barbara</surname><given-names>G</given-names></name></person-group><article-title>Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><fpage>392</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">19174797</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piche</surname><given-names>T</given-names></name><name><surname>Saint-Paul</surname><given-names>MC</given-names></name><name><surname>Dainese</surname><given-names>R</given-names></name><name><surname>Marine-Barjoan</surname><given-names>E</given-names></name><name><surname>Iannelli</surname><given-names>A</given-names></name><name><surname>Montoya</surname><given-names>ML</given-names></name><name><surname>Peyron</surname><given-names>JF</given-names></name><name><surname>Czerucka</surname><given-names>D</given-names></name><name><surname>Cherikh</surname><given-names>F</given-names></name><name><surname>Filippi</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>A</given-names></name><name><surname>H&#x000e9;buterne</surname><given-names>X</given-names></name></person-group><article-title>Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome</article-title><source>Gut</source><year>2008</year><volume>57</volume><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">18194987</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MM</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Prabhakar</surname><given-names>M</given-names></name><name><surname>Pennaneach</surname><given-names>CJ</given-names></name><name><surname>Aro</surname><given-names>P</given-names></name><name><surname>Ronkainen</surname><given-names>J</given-names></name><name><surname>Storskrubb</surname><given-names>T</given-names></name><name><surname>Harmsen</surname><given-names>WS</given-names></name><name><surname>Zinsmeister</surname><given-names>AR</given-names></name><name><surname>Agreus</surname><given-names>L</given-names></name></person-group><article-title>Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia</article-title><source>Aliment Pharmacol Ther</source><year>2009</year><volume>29</volume><fpage>765</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">19183150</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbara</surname><given-names>G</given-names></name><name><surname>Stanghellini</surname><given-names>V</given-names></name><name><surname>De Giorgio</surname><given-names>R</given-names></name><name><surname>Cremon</surname><given-names>C</given-names></name><name><surname>Cottrell</surname><given-names>GS</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Pasquinelli</surname><given-names>G</given-names></name><name><surname>Morselli-Labate</surname><given-names>AM</given-names></name><name><surname>Grady</surname><given-names>EF</given-names></name><name><surname>Bunnett</surname><given-names>NW</given-names></name><name><surname>Collins</surname><given-names>SM</given-names></name><name><surname>Corinaldesi</surname><given-names>R</given-names></name></person-group><article-title>Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">14988823</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilarte</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>J</given-names></name><name><surname>de Torres</surname><given-names>I</given-names></name><name><surname>Alonso</surname><given-names>C</given-names></name><name><surname>Vicario</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>L</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>C</given-names></name><name><surname>Casellas</surname><given-names>F</given-names></name><name><surname>Saperas</surname><given-names>E</given-names></name><name><surname>Malagelada</surname><given-names>JR</given-names></name></person-group><article-title>Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum</article-title><source>Gut</source><year>2007</year><volume>56</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">17005763</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>YB</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kwon</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Cho</surname><given-names>SW</given-names></name></person-group><article-title>The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors</article-title><source>J Gastroenterol Hepatol</source><year>2008</year><volume>23</volume><fpage>1689</fpage><lpage>1694</lpage><pub-id pub-id-type="pmid">19120860</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanahan</surname><given-names>F</given-names></name><name><surname>Denburg</surname><given-names>JA</given-names></name><name><surname>Fox</surname><given-names>J</given-names></name><name><surname>Bienenstock</surname><given-names>J</given-names></name><name><surname>Befus</surname><given-names>D</given-names></name></person-group><article-title>Mast cell heterogeneity: effects of neuroenteric peptides on histamine release</article-title><source>J Immunol</source><year>1985</year><volume>135</volume><fpage>1331</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">2409146</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stead</surname><given-names>RH</given-names></name><name><surname>Tomioka</surname><given-names>M</given-names></name><name><surname>Quinonez</surname><given-names>G</given-names></name><name><surname>Simon</surname><given-names>GT</given-names></name><name><surname>Felten</surname><given-names>SY</given-names></name><name><surname>Bienenstock</surname><given-names>J</given-names></name></person-group><article-title>Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves</article-title><source>Proc Natl Acad Sci U S A</source><year>1987</year><volume>84</volume><fpage>2975</fpage><lpage>2979</lpage><pub-id pub-id-type="pmid">2437589</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>HZ</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>GY</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Wood</surname><given-names>JD</given-names></name></person-group><article-title>Serine proteases excite myenteric neurons through protease-activated receptors in guinea pig small intestine</article-title><source>Gastroenterology</source><year>2002</year><volume>123</volume><fpage>1554</fpage><lpage>1564</lpage><pub-id pub-id-type="pmid">12404230</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandtzaeg</surname><given-names>P</given-names></name></person-group><article-title>Food allergy: separating the science from the mythology</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2010</year><volume>7</volume><fpage>380</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">20606633</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valent</surname><given-names>P</given-names></name></person-group><article-title>Systemic mastocytosis</article-title><source>Cancer Treat Res</source><year>2008</year><volume>142</volume><fpage>399</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">18283797</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corinaldesi</surname><given-names>R</given-names></name><name><surname>Stanghellini</surname><given-names>V</given-names></name><name><surname>Cremon</surname><given-names>C</given-names></name><name><surname>Gargano</surname><given-names>L</given-names></name><name><surname>Cogliandro</surname><given-names>RF</given-names></name><name><surname>De Giorgio</surname><given-names>R</given-names></name><name><surname>Bartesaghi</surname><given-names>G</given-names></name><name><surname>Canovi</surname><given-names>B</given-names></name><name><surname>Barbara</surname><given-names>G</given-names></name></person-group><article-title>Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study</article-title><source>Aliment Pharmacol Ther</source><year>2009</year><volume>30</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">19438846</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klooker</surname><given-names>TK</given-names></name><name><surname>Braak</surname><given-names>B</given-names></name><name><surname>Koopman</surname><given-names>KE</given-names></name><name><surname>Welting</surname><given-names>O</given-names></name><name><surname>Wouters</surname><given-names>MM</given-names></name><name><surname>van der Heide</surname><given-names>S</given-names></name><name><surname>Schemann</surname><given-names>M</given-names></name><name><surname>Bischoff</surname><given-names>SC</given-names></name><name><surname>van den Wijngaard</surname><given-names>RM</given-names></name><name><surname>Boeckxstaens</surname><given-names>GE</given-names></name></person-group><article-title>The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome</article-title><source>Gut</source><year>2010</year><volume>59</volume><fpage>1213</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">20650926</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>SM</given-names></name><name><surname>Bercik</surname><given-names>P</given-names></name></person-group><article-title>The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>2003</fpage><lpage>2014</lpage><pub-id pub-id-type="pmid">19457424</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradesi</surname><given-names>S</given-names></name><name><surname>Eutamene</surname><given-names>H</given-names></name><name><surname>Garcia-Villar</surname><given-names>R</given-names></name><name><surname>Fioramonti</surname><given-names>J</given-names></name><name><surname>Bu&#x000e9;no</surname><given-names>L</given-names></name></person-group><article-title>Acute and chronic stress differently affect visceral sensitivity to rectal distension in female rats</article-title><source>Neurogastroenterol Motil</source><year>2002</year><volume>14</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">11874556</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukudo</surname><given-names>S</given-names></name></person-group><article-title>Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation</article-title><source>J Gastroenterol</source><year>2007</year><volume>42</volume><issue>Suppl 17</issue><fpage>48</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17238026</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikfar</surname><given-names>S</given-names></name><name><surname>Rahimi</surname><given-names>R</given-names></name><name><surname>Rahimi</surname><given-names>F</given-names></name><name><surname>Derakhshani</surname><given-names>S</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials</article-title><source>Dis Colon Rectum</source><year>2008</year><volume>51</volume><fpage>1775</fpage><lpage>1780</lpage><pub-id pub-id-type="pmid">18465170</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karamanolis</surname><given-names>G</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name></person-group><article-title>Nutrition and motility disorders</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2006</year><volume>20</volume><fpage>485</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">16782525</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischoff</surname><given-names>SC</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><name><surname>Meier</surname><given-names>PN</given-names></name><name><surname>Zeck-Kapp</surname><given-names>G</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name></person-group><article-title>Clinical significance of the colonoscopic allergen provocation test</article-title><source>Int Arch Allergy Immunol</source><year>1997</year><volume>113</volume><fpage>348</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">9130574</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whorwell</surname><given-names>PJ</given-names></name><name><surname>Bentley</surname><given-names>KJ</given-names></name><name><surname>Atkinson</surname><given-names>W</given-names></name><name><surname>Sheldon</surname><given-names>TA</given-names></name></person-group><article-title>IgG antibodies to foods in IBS</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>1204</fpage><pub-id pub-id-type="pmid">16009697</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zar</surname><given-names>S</given-names></name><name><surname>Benson</surname><given-names>MJ</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name></person-group><article-title>Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><fpage>1550</fpage><lpage>1557</lpage><pub-id pub-id-type="pmid">15984980</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Gorman</surname><given-names>H</given-names></name></person-group><article-title>Intestinal permeability and irritable bowel syndrome</article-title><source>Neurogastroenterol Motil</source><year>2007</year><volume>19</volume><fpage>545</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">17593135</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>N</given-names></name><name><surname>Huntley</surname><given-names>B</given-names></name><name><surname>Beech</surname><given-names>T</given-names></name><name><surname>Knight</surname><given-names>W</given-names></name><name><surname>Knight</surname><given-names>H</given-names></name><name><surname>Corrigan</surname><given-names>CJ</given-names></name></person-group><article-title>Increased prevalence of gastrointestinal symptoms in patients with allergic disease</article-title><source>Postgrad Med J</source><year>2007</year><volume>83</volume><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">17344573</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>OY</given-names></name><name><surname>Yoon</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>HL</given-names></name><name><surname>Yoon</surname><given-names>BC</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Kee</surname><given-names>CS</given-names></name></person-group><article-title>Bronchial hyperresponsiveness in irritable bowel syndrome</article-title><source>Dig Dis Sci</source><year>2005</year><volume>50</volume><fpage>1688</fpage><lpage>1691</lpage><pub-id pub-id-type="pmid">16133970</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tougas</surname><given-names>G</given-names></name></person-group><article-title>The autonomic nervous system in functional bowel disorders</article-title><source>Gut</source><year>2000</year><volume>47</volume><issue>Suppl 4</issue><fpage>iv78</fpage><lpage>iv80</lpage><pub-id pub-id-type="pmid">11076926</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keita</surname><given-names>AV</given-names></name><name><surname>S&#x000f6;derholm</surname><given-names>JD</given-names></name></person-group><article-title>The intestinal barrier and its regulation by neuroimmune factors</article-title><source>Neurogastroenterol Motil</source><year>2010</year><volume>22</volume><fpage>718</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">20377785</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiller</surname><given-names>R</given-names></name><name><surname>Garsed</surname><given-names>K</given-names></name></person-group><article-title>Infection, inflammation, and the irritable bowel syndrome</article-title><source>Dig Liver Dis</source><year>2009</year><volume>41</volume><fpage>844</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">19716778</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>PR</given-names></name><name><surname>Shepherd</surname><given-names>SJ</given-names></name></person-group><article-title>Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach</article-title><source>J Gastroenterol Hepatol</source><year>2010</year><volume>25</volume><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">20136989</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>The Brain - Gut axis in irritable bowel syndrome (IBS).</p></caption><graphic xlink:href="apa-1-36-g001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Proposed dualistic treatment model of irritable bowel syndrome.</p></caption><graphic xlink:href="apa-1-36-g002"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Rome III diagnostic criteria for irritable bowel syndrome</p></caption><graphic xlink:href="apa-1-36-i001"/><table-wrap-foot><fn><p><sup>*</sup>Discomfort means an uncomfortable sensation not described as pain.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Studies of intestinal mast cell infiltration in irritable bowel syndrome</p></caption><graphic xlink:href="apa-1-36-i002"/></table-wrap></floats-group></article>